The role of HMGB1 in BMSC transplantation for treating MODS in rats
The effect of bone marrow mesenchymal stem cells (BMSCs) in treatment for multiple organ dysfunction syndrome (MODS) remains unknown and the mechanism is still unclear. Therefore, the goal of this study is to investigate the effects of intracellular high mobility group box 1 protein (HMGB1) on BMSCs treating for MODS. The rats were given 15% blood loss plus 1 mg/kg lipopolysaccharide (LPS) via lower extremity superficial venous, then randomly allocated into four groups: sham group, MODS group, MODS plus BMSC group, MODS plus ethyl pyruvate (EP) group, MODS plus BMSCs plus EP group. Twenty-four hours later, rats in groups were sacrificed and then the blood and tissues were collected to evaluate the changes of tissue histopathology, cell apoptosis, inflammation level and organ function. The HGMB1 expression was monitored by RT-qPCR and Western blot. The expression of RAGE/TLR2/TLR4 and NF-κB at the protein levels was also assessed. BMSCs and/or EP exhibits an outstanding protective effect against LPS-induced histopathological injury by improving cell apoptosis, inflammatory response and the organ dysfunction but no effect on BMSC homing to the injury site. Moreover, BMSCs and/or EP inhibited LPS-induced upregulation of HMGB1, RAGE, TLR2 and TLR4 expression at protein levels and compromised p65 phosphorylation in the rat model of MODS. These findings suggest that HMGB1 is involved in BMSC treatment for MODS, through regulation of the TLR2, TLR4-mediated NF-κB signal pathway. It suggests that HMGB1 is an attractive potential target for the development of new therapeutic strategies for MODS.
KeywordsMODS BMSC HMGB1 Lipopolysaccharide NF-κB signal pathway
Compliance with ethical standards
Rat care was in full compliance with the Guide for the Care and Use of Laboratory Animals and the use of laboratory animals in the research and all studies were approved by the Animal Ethical Committee of Kunming Medical University.
Conflict of interest
The authors declare that they have no conflicts of interest.
- Al-Khafaji AH, Sharma S, Eschun G (2017) Multiple organ dysfunction syndrome in sepsis. Available at https://emedicine.medscape.com/article/169640-overview
- Hayakawa K, Pham L-DD, Arai K, Lo EH (2013) High-mobility group box 1: an amplifier of stem and progenitor cell activity after stroke. Brain Edema XV. Springer:31–38Google Scholar
- Heming Y, Maoxing Y, Jianzhong L (2000) The changes of gastric hormones in MODS rats models made of hemorrhage and endotoxin. J Traumatic Surg 2:86–88Google Scholar
- Ling Bin CJ, Wang T-h, Pan X-h, Sun J, Liu P (2010a) Apoptotic protease activating factor-1 expression in the heart, liver and lung of rabbits with multiple organ dysfunction syndrome following bone marrow mesenchymal stem cells transplantation. J Clin Rehab Tissue Eng Res 14:4Google Scholar
- Ling Bin JC, Wang T, Pan X, Sun J (2010b) Bone marrow mesenchymal stem cells transplantation down-regulates the mRNA expression of the apoptotic factor Apaf-1 in hearts, spleens, and kidneys of rabbits with MODS. J Kunming Med Univ 31:6Google Scholar
- Song Qiong LB, Sun J, Liu P (2009) Treatment of multiple organ dysfunction syndrome by administration of mesenchymal stem cells. Int J Surg 36:3Google Scholar
- Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K (2011) Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 5:146–150CrossRefPubMedGoogle Scholar